Cortical 11C-PIB uptake is associated with age, APOE genotype, and gender in 'healthy aging'

Journal of Alzheimer's Disease

Volumn 41, Issue 1, 2014, Pages 193-202

  Scheinin, Noora M ^a   Wikman, Kristina ^a   Jula, Antti ^b   Perola, Markus ^b   Vahlberg, Tero ^c   Rokka, Johanna ^a   Någren, Kjell ^d   Viitanen, Matti ^e,f   Rinne, Juha O ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e TURKU CITY HOSPITAL   (Finland)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Aging; amyloid; APOE; gender; PET; PIB; positron emission tomography

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; PITTSBURGH COMPOUND B; AMYLOID; APOLIPOPROTEIN E4; BENZOTHIAZOLE DERIVATIVE; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGE; AGED; AGING; ARTICLE; BRAIN CORTEX; CEREBELLUM CORTEX; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DRUG UPTAKE; FEMALE; FRONTAL CORTEX; GENDER; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NEUROPSYCHOLOGICAL TEST; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL PARAMETRIC MAPPING; VERY ELDERLY; BRAIN; DIAGNOSTIC USE; EDUCATIONAL STATUS; GENETICS; GENOTYPING TECHNIQUE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SCINTISCANNING; SEXUAL DEVELOPMENT;

AGED; AGED, 80 AND OVER; AGING; AMYLOID; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BENZOTHIAZOLES; BRAIN; CROSS-SECTIONAL STUDIES; EDUCATIONAL STATUS; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SEX CHARACTERISTICS;

EID: 84902275156     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132783     Document Type: Article

References (44)

1. Price J, Morris J (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45, 358-368.
2. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo O, Szoeke C, Salvado O, Head R, Martins, Masters CL, Ames D, Villemagne VL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31, 1275-1283.
3. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, Australian Imaging Biomarkers, Lifestyle (AIBL) Research Group (2013) Amyloid p deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 12, 357-367.
4. Hardy J (1997) Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20, 154-159.
5. Hardy J, Selkoe D (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
6. Klunk WE, Engler H, Nordberg A, Wang YM, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55, 306-319.
7. Mintun M, Larossa G, Sheline Y, Dence C, Lee S, Mach R, Klunk W, Mathis C, DeKosky S, Morris J (2006) [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67, 446-452.
8. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC (2007) Beta-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844.
9. Rowe C, Ng S, Ackermann U, Gong S, Pike K, Savage G, Cowie T, Dickinson K, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk W, Mathis C, Price J, Masters C, Villemagne V (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68, 1718-1725.
10. Aizenstein H, Nebes R, Saxton J, Price J, Mathis C, Tsopelas N, Ziolko S, James J, Snitz B, Houck P, Bi W, Cohen A, Lopresti B, DeKosky S, Halligan E, Klunk W (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65, 1509-1517.
11. Jack CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC (2008) C-II PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131, 665-680.
12. Scheinin NM, Aalto S, Koikkalainen J, Lötjönen J, Karrasch M, Kemppainen N, Viitanen M, Nagren K, Helin S, Scheinin M, Rinne JO (2009) Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 73, 1186-1192.
13. Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Van-denberghe R, Perani D, Forsberg A, Langström B, Scheinin N, Karrasch M, Nagren K, Grimmer T, Miederer I, Edison P, Okello A, Van Laere K, Nelissen N, Vandenbulcke M, Gari-botto V, Almkvist O, Kalbe E, Hinz R, Herholz K (2013) A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging 40, 104-114.
14. Sugihara S, Ogawa A, Nakazato Y, Yamaguchi H (1995) Cerebral beta amyloid deposition in patients with malignant neoplasms: Its prevalence with aging and effects of radiation therapy on vascular amyloid. Acta Neuropathol 90, 135-141.
15. Meye M, Tschanz J, Norton M, Welsh-Bohmer K, Steffens D, Wyse B, Breitner J (1998) APOE genotype predicts when-not whether-oneis predisposedtodevelop Alzheimer disease. Nat Genet 19, 321-322.
16. Khachaturian A, Corcoran C, Mayer L, Zandi P, Breitner J (2004) Apolipoprotein Eepsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Arch Gen Psychiatry 61, 518-524.
17. Reiman E, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanon N, Keppler J, Reeder S, Langbaum J, Alexander G, Klunk W, Mathis C, Price J, Aizenstein H, DeKosky S, Caselli R (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 106, 6820-6825.
18. Bertram L, Tanzi R (2005) The genetic epidemiology of neu-rodegenerative disease. J Clin Invest 115, 1449-1457.
19. Pike KE, Ellis KA, Villemagne VL, Good N, Chételat G, Ames D, Szoeke C, Laws SM, Verdile G, Martins RN, Masters CL, Rowe CC (2011) Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. Neuropsychologia 49, 2384-2390.
20. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39, 1159-1165.
21. Hanninen T, Pulliainen V, Sotaniemi M, Hokkanen L, Salo J, Hietanen M (2010) Early detection of cognitive changes in memory diseases: New cut-off scores for the Finnish version of CERAD neuropsychological battery. Duodecim 126, 2013-2021.
22. Chandler MJ, Lacritz LH, Hynan LS, Barnard HD, Allen G, Deschner M, Weiner MF, Cullum CM (2005) A total score for the CERAD neuropsychological battery. Neurology 65, 102-106.
23. Kemppainen N, Aalto S, Wilson I, Nagren K, Helin S, Brück A, Oikonen V, Kailajarvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO (2006) Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 67, 1575-1580.
24. Kemppainen N, Aalto S, Wilson I, Nagren K, Helin S, Brück A, Oikonen V, Kailajarvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68, 1603-1606.
25. Aalto S, Scheinin NM, Kemppainen N, Nagren K, Kailajarvi M, Leinonen M, Scheinin M, Rinne, JO (2009) Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data. Eur J Nucl Med Mol Imaging 36, 1651-1660.
26. Klunk W, Wang Y, Huang G, Debnath M, Holt D, Shao L, Hamilton R, Ikonomovic M, DeKosky S, Mathis C (2003) The binding of 2-(4'-methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 23, 2086-2092.
27. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu XL, Meltzer CC, Schimme K, Tsopelas ND, DeKosky ST, Price JC (2005) Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: A comparative analysis. J Nucl Med 46, 1959-1972.
28. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljung WR, Debnath ML, Hope CE, Isanski BA, Hamilton R, DeKosky ST (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain131, 1630-1645.
29. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgea P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC (2011) Longitudinal assessment of Afj and cognition in aging and Alzheimer disease. Ann Neurol 69, 181-192.
30. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA (2009) Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 66, 1469-1475.
31. Sojkova J, Zhou Y, An Y, Kraut MA, Ferrucci L, Wong DF, Resnick SM (2011) Longitudinal patterns of fj-amyloid deposition in nondemented older adults. Arch Neurol 68, 644-649.
32. Kemppainen NM, Aalto S, Karrasch M, Nagren K, Savisto N, Oikonen V, Viitanen M, Parkkola R, Rinne JO (2008) Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol 63, 112-118.
33. Schmechel D, Saunders A, Strittmatter W, Crain B, Hulett Ce, Joo S, Pericak-Vance M, Goldgaber D, Roses D (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90, 9649-9653.
34. Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, Niinisto L, Halonen P, Kontula K (1995) Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 333, 1242-1247.
35. Ritchie K, Dupuy A (1999) The current status of apo E4 as a risk factor for Alzheimer's disease: An epidemiological perspective. Int J Geriatr Psychiatry 14, 695-700.
36. Martins I, Hone E, Foster J, Sünram-Lea S, Gnjec A, Fuller S, Nolan D, Gandy S, Martins R (2006) Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 11, 721-736.
37. Drzezga A, Grimmer T, Henriksen G, Mühlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschlage A, Riemen-schneider M, Wester H, Foerstl H, Schwaiger M, Kurz A (2009) Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72, 1487-1494.
38. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67, 122-131.
39. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Investigators BCT (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070.
40. Choo I, Lee DY, Kim JW, Seo EH, Lee DS, Kim YK, Kim SG, Park SY, Woo JI, Yoon EJ (2011) Relationship of amyloid-fj burden with age-at-onset in Alzheimer disease. Am J Geriatr Psychiatry 19, 627-634.
41. Resnick SM, Sojkova J, Zhou Y, An Y, Yu W, Holt DP, Dannals RF, Mathis CA, Klunk WE, Ferrucci L, Kraut MA, Wong DF (2010) Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 74, 807-815.
42. Okello A, Koivunen J, Edison P, Archer H, Turkheimer F, Nagren K, Bullock R, Walker Z, Kennedy A, Fox N, Rossor M, Rinne J, Brooks D (2009) Conversion of amyloid positive and negative MCI to AD over 3 years. An 11C-PIB PET study. Neurology 73, 754-760.
43. Terwel D, Muyllaert D, Dewachter I, Borghgraef P, Croes S, Devijver H, Van Leuven F (2008) Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol 172, 786-798.
44. Sultana R, Perluigi M, Butterfield D (2009) Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: Role of Abeta in pathogenesis. Acta Neuropathol 118, 131-150.